Publications by authors named "Valter Torri"

Claim this Profile
P
Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial.
Michele Reni, Marina Macchini, Giulia Orsi, Letizia Procaccio, Giuseppe Malleo, Valter Torri

Lancet· December 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and Design of the AUSTRAL trial: An Open-Label, Multicenter, Phase II Study Evaluating Radiotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Stage III NSCLC Patients With Thoracic Relapses and/or Oligometastases After the PACIFIC Regimen.
Andrea Riccardo Filippi, Eliana Rulli, Diego Signorelli, Jonas Willmann, Andrè Durham, Valter Torri

Clin Lung Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Total neoadjuvant therapy followed by non-operative management or surgery in stage II-III rectal cancer (NO-CUT): a multicentre, single-arm, phase 2 trial.
Alessio Amatu, Giorgio Patelli, Maria Giulia Zampino, Francesca Bergamo, Stefania Mosconi, Valter Torri

Lancet Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation of ORR and PFS with OS outcomes in phase III trials of immunotherapy in advanced NSCLC: Systematic review and meta-analysis.
Fabio Salomone, Massimo Di Maio, Angela Viggiano, Luigi Liguori, Carminia Maria Della Corte, Valter Torri

Crit Rev Oncol Hematol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant vs perioperative chemo-immunotherapy according to pathological response in resectable non-small cell lung cancer: a reconstructed individual patient data meta-analysis.
Antonio Nuccio, Fabio Salomone, Alberto Servetto, Biagio Ricciuti, Daniele Marinelli, Valter Torri

J Natl Cancer Inst· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of platinum-based chemotherapy and CTLA-4 inhibition on acquired resistance to first-line anti-PD-1/PD-L1 agents in non-small cell lung cancer: a systematic review and reconstructed individual patient data analysis.
Sara Oresti, Fabio Salomone, Antonio Nuccio, Francesca Rita Ogliari, Silvia Teresa Riva, Valter Torri

EClinicalMedicine· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The molecular and functional landscape of resistance to FOLFIRI chemotherapy in metastatic colorectal cancer.
Marco Avolio, Simonetta M Leto, Francesco Sassi, Barbara Lupo, Elena Grassi, Valter Torri

Cancer Discov· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mepitel® film versus standard care for the prevention of skin toxicity in breast cancer patients treated with adjuvant radiotherapy: A randomized controlled trial.
Dario Valcarenghi, Angela Tolotti, Hansjoerg Vees, Valter Torri, Sarah Jayne Liptrott

Clin Transl Radiat Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of a Silicone Mask Improves the Reproducibility of Tooth Color Assessment for Whitening Clinical Trials.
Pier Francesco Porciani, Simone Grandini, Caterina Perra, Luca Porcu, Valter Torri

Int J Dent· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevention of falls in hospitalized patients-evaluation of the effectiveness of a monitoring system (Verso Vision) developed with artificial intelligence.
Corrado Gervasi, Erik Perego, Francesca Galli, Valter Torri, Massimo Castoldi

Front Digit Health· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry.
Alessio Cortellini, Leonardo Brunetti, Giuseppina Rita Di Fazio, Edoardo Garbo, David J Pinato, Valter Torri

J Immunother Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Commentary on "Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC".
Robert B Cameron, Jacobi B Hines, Valter Torri, Marina C Garassino

J Thorac Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How to Test for Predicting Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer? Evidence From the Secondary Analysis of Biomarkers of CALGB/SWOG 80405.
Andrea Sartore-Bianchi, Silvia Marsoni, Alessio Amatu, Valter Torri, Emanuela Bonoldi

J Clin Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Response Letter by Cameron et al.
Robert B Cameron, Jacobi B Hines, Valter Torri, Marina C Garassino

J Thorac Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC.
Jacobi B Hines, Robert B Cameron, Alessandra Esposito, Leeseul Kim, Luca Porcu, Valter Torri

J Thorac Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% Fund.
Luigi Cerbone, Sara Delfanti, Stefania Crivellari, Antonina Maria De Angelis, Laura Mazzeo, Valter Torri

Tumori· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant or Perioperative Approach in Lung Cancer.
Marina Chiara Garassino, Valter Torri

N Engl J Med· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors.
Sara Manglaviti, Marta Bini, Giulia Apollonio, Ernesto Zecca, Giulia Galli, Valter Torri

Lung Cancer· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies.
Antonio Nuccio, Giuseppe Viscardi, Fabio Salomone, Alberto Servetto, Francesco Maria Venanzi, Valter Torri

Eur J Cancer· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studies.
Federica Miglietta, Maria Vittoria Dieci, Tommaso Giarratano, Valter Torri, Mario Giuliano

Eur J Cancer· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer?
Robert B Cameron, Jacobi B Hines, Valter Torri, Luca Porcu, Jessica Donington

Ther Adv Med Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A systematic review and meta-analysis on the optimal treatment duration of checkpoint inhibitoRS in solid tumors: The OTHERS study.
Giorgio Bogani, Michela Cinquini, Diego Signorelli, Elio G Pizzutilo, Rebecca Romanò, Valter Torri

Crit Rev Oncol Hematol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis.
Giuseppe Lo Russo, Arsela Prelaj, James Dolezal, Teresa Beninato, Luca Agnelli, Valter Torri

J Immunother Cancer· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer.
Maria Ornella Nicoletto, Alessandra Baldoni, Francesco Cavallin, Andrea Grego, Cristina Falci, Valter Torri

Ther Adv Med Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DESTINY-Breast03 trial: some questions remain.
Serena Di Cosimo, Giovanni Apolone, Vera Cappelletti, Valter Torri

Lancet· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis